EGFR and head and neck squamous cell carcinoma: Since the publication of combined radioimmunotherapy with the EGF receptor antibody cetuximab in SCCHN of the Bonner trial in 2006 [28,29] though, application of these drugs in adenoid cystic carcinoma seemed feasible in view of potential increase of radiation sensitivity and - albeit modest - systemic activity given the relatively mild toxicity profile of EGFR antibodies.